C
Chuan Gu
Researcher at Shanghai Jiao Tong University
Publications - 9
Citations - 141
Chuan Gu is an academic researcher from Shanghai Jiao Tong University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 4 publications receiving 87 citations.
Papers
More filters
Journal ArticleDOI
Hydrogen-rich saline protects against acute lung injury induced by extensive burn in rat model.
Yong Fang,Xiu-Jun Fu,Chuan Gu,Peng Xu,Ying Wang,Wei-Rong Yu,Qiang Sun,Xuejun Sun,Xuejun Sun,Min Yao,Min Yao +10 more
TL;DR: Intraperitoneal administration of hydrogen-rich saline improves pulmonary function by reducing oxidative stress and inflammatory response in severe burn-induced acute lung injury.
Journal ArticleDOI
Ulinastatin improves pulmonary function in severe burn-induced acute lung injury by attenuating inflammatory response.
TL;DR: Results indicate that the inhibitory effects of ulinastatin on inflammatory mediator production, neutrophil activation, and microvascular permeability are associated with the recovery of pulmonary functions in severe burn-induced acute lung injury and suggest that ulinastsatin may serve as a potential therapeutic administration in critical burn care.
Journal ArticleDOI
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study.
Yuankai Shi,Gongyan Chen,Xinkang Wang,Yunpeng Liu,Lin Wu,Yanrong Hao,Chunling Liu,Shuyang Zhu,Xiaodong Zhang,Yuping Li,Jiwei Liu,Lejie Cao,Ying Cheng,Hui-fang Zhao,Shucai Zhang,Aimin Zang,Jiuwei Cui,Jian Feng,Nong Yang,Fei Liu,Yong Jiang,Chuan Gu +21 more
TL;DR: Furmonertinib (AST2818) is an irreversible, selective, third-generation EGFR tyrosine-kinase inhibitor as discussed by the authors , which is a new potential treatment option for this population.
Journal ArticleDOI
Central nervous system efficacy of furmonertinib (AST2818) versus gefitinib as first-line treatment for EGFR mutated non-small cell lung cancer: results from the FURLONG study.
Yuankai Shi,Gongyan Chen,Xinkang Wang,Yunpeng Liu,Lin Wu,Yanrong Hao,Chunling Liu,Shuyang Zhu,Xiaodong Zhang,Yuping Li,Jiwei Liu,Lejie Cao,Ying Chen,Hui-fang Zhao,Shucai Zhang,Aimin Zang,Jiuwei Cui,Jian Feng,Nong Yang,Meilin Liu,Yong Jiang,Chuan Gu +21 more
TL;DR: In this article , the authors reported the CNS efficacy of furmonertinib compared with gefitinib in untreated EGFR-sensitizing mutation-positive NSCLC from the FURLONG study.
Journal ArticleDOI
SUMO-specific protease 2 (SENP2) suppresses keratinocyte migration by targeting NDR1 for de-SUMOylation.
Ning Xiao,Ning Xiao,Hui Li,Wei-Rong Yu,Chuan Gu,Houshun Fang,Yinbo Peng,He-shui Mao,Yong Fang,Wei Ni,Min Yao +10 more
TL;DR: Significantly, low‐level laser (LLL) irradiation increases NDR1 SUMOylation and subsequent p38/ERK1/2 activation via down‐regulation of SENP2, leading to faster keratinocyte migration, filling the gaps that linger in the basic mechanisms underlying LLL therapy.